Ningbo Menovo Pharmaceutical Co., Ltd. (China)

Ningbo Menovo Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Ningbo, Zhejiang Province. It was listed on the Shanghai Stock Exchange on April 7, 2017, with the stock abbreviation "Menovo" and stock code 603538. The company is a comprehensive international pharmaceutical technology manufacturing enterprise specializing in the research, development, production, and sales of specialty APIs (including intermediates) and finished drugs. It is one of the domestic enterprises with the most varieties of specialty APIs exported to Europe and has been honored as one of the "Top 20 CDMO Enterprises in China" for multiple years. The company's products cover the treatment areas of cardiovascular, central nervous system, and gastrointestinal tract. Core products such as Valsartan, Losartan, Clopidogrel, Perindopril, Rosuvastatin Calcium, Atorvastatin Calcium, and Pregabalin have formed a complete industrial chain commercialization system for research, development, production, and sales. With rigorous quality management and EHS management capabilities, solid process development, high-standard large-scale production capabilities, as well as efficient and effective team combat capabilities, the company has established long-term and stable cooperation relationships with well-known pharmaceutical companies at home and abroad. It has gained high brand international recognition and competitive advantages in the CDMO and specialty API industries. Since its listing, the company has leveraged the capital market and driven growth through both internal and external expansion. While strengthening its specialty API business, it has firmly implemented an integrated strategy of "pharmaceutical intermediates, APIs, and formulations," expanding and extending upstream intermediates and downstream formulation businesses to further improve its industrial chain layout and fully expand its integrated advantages. At the same time, based on its competitive advantages in the specialty API field and customer network resources, the company continues to develop its CDMO business and accelerate the construction of a comprehensive CDMO one-stop service platform. Through continuous improvement of multi-dimensional strategic layout, with CDMO business and integrated formulation business as the core, the company actively engages in the development and commercialization of cutting-edge medical products, aiming to make Menovo a leading, internationally renowned, and highly competitive international pharmaceutical technology manufacturing enterprise.